'Time is brain' also in multiple sclerosis

Multiple Sclerosis

Volumn 15, Issue 10, 2009, Pages 1133-1134

  Freedman, Mark S ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; PLACEBO;

BRAIN SIZE; DOSAGE SCHEDULE COMPARISON; EARLY INTERVENTION; EDITORIAL; HEALTH CARE COST; HUMAN; IMAGING; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; NERVE FIBER DEGENERATION; NUCLEAR MAGNETIC RESONANCE IMAGING; STROKE; TRANSIENT ISCHEMIC ATTACK;

BRAIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PEPTIDES; TIME FACTORS;

EID: 72449168080     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509345920     Document Type: Editorial

References (8)

1. Goodin DS and Bates D. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler 2009; 15: 1175-1182.
2. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008; 71(24 Suppl 3): S8-13.
3. Miller DH, Weinshenker BG, Filippi M, et al. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler 2008; 14: 1157-1174.
4. 4. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007 370: 389-397. (Pubitemid 47189673)
5. Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40: 2276-2293.
6. Chandratheva A, Mehta Z, Geraghty OC, Marquardt L, Rothwell PM. Population-based study of risk and predictors of stroke in the first few hours after a TIA. Neurology 2009; 72: 1941-1947.
7. Kappos L, Freedman MS, Polman CH, et al. Long-term impact of early treatment with interferon beta-lb after a first clinical event suggestive of multiple sclerosis. Lancet Neurology 2009; (in press).
8. Pittock SJ. Does benign multiple sclerosis today imply benign multiple sclerosis tomorrow?: implications for treatment. Neurology 2007; 68: 480-481.